findmyKOL

Patrick Forde, MD

Enriched profile

Prendergast Professor of Immuno-Oncology, Trinity College Dublin / Trinity St James's Cancer Institute; Consultant Medical Oncologist, St James's Hospital Dublin; Professor of Oncology, Johns Hopkins University School of Medicine · Trinity College Dublin

ORCIDNPI
Region🇺🇸 Baltimore, MD · Northeast · United StatesSpecialtyHematology / OncologyFocusCancer Immunotherapy and Biomarkers+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Patrick Forde is Prendergast Professor of Immuno-Oncology, Trinity College Dublin / Trinity St James's Cancer Institute; Consultant Medical Oncologist, St James's Hospital Dublin; Professor of Oncology, Johns Hopkins University School of Medicine at Trinity College Dublin. OpenAlex indexes 544 publications with 19,787 citations (h-index 66); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Patrick Forde, MD, is Prendergast Professor of Immuno-Oncology, Trinity College Dublin / Trinity St James's Cancer Institute. The public record shows 544 publications with 19,787 citations (h-index 66), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 27 companies.

  • Most recent indexed publication: 2026 · JCO precision oncology
  • Top research focus: Cancer Immunotherapy and Biomarkers
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 27 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)3 trialsSmall Cell Lung Carcinoma3 trialsMesothelioma2 trialsMesothelioma, Malignant1 trial

Research focus

OpenAlex concept fingerprint
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsCancer Genomics and DiagnosticsLung Cancer Research StudiesLung Cancer Diagnosis and Treatment

Drugs & molecules

across trials, industry payments and publications
Imfinzigeneric · DurvalumabClinical trialsIndustry payments9Publications4Opdivogeneric · NivolumabClinical trialsIndustry payments3Publications6Libtayogeneric · CemiplimabClinical trialsIndustry payments50Publications

Works with

trial sponsors and companies reporting payments
Regeneron Pharmaceuticals, Inc.Clinical trialsIndustry payments60AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments36E.R. Squibb & Sons, L.L.C.Clinical trialsIndustry payments33

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
544publications

Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.

19,787citations

Total citations across indexed works.

66h-index

Hirsch index (OpenAlex). i10-index 161.

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials
27companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    64.1%
    Kinase inhibitor64.1%
    Tagrisso72%Xalkori28%
    Part D<11 patients
  • Nervous system

    20.5%
    Phenothiazine20.5%
    Prochlorperazine Maleate100%
    Part D<11 patients
  • Genitourinary & hormones

    15.4%
    alpha-Adrenergic Blocker15.4%
    Tamsulosin Hcl100%
    Part D<11 patients
Where care is delivered (Part B)87.1% facility · 12.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

100 congress contributions (2009–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/patrick-forde-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/patrick-forde-3aa7b745

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    people.tcd.ie/fordep1

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →people.tcd.ie
5 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Principal Investigator

    CheckMate 816 trial (neoadjuvant nivolumab plus chemotherapy in resectable NSCLC)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nejm.org
  • Member

    American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC), Society for Immunotherapy of Cancer (SITC), American Association for Cancer Research (AACR) …

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tcd.ie

Awards & honors

honors on the public record
3 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.